Adult triclabendazole-resistant Fasciola hepatica: morphological changes in the tegument and gut following in vivo treatment with artemether in the rat model | Journal of Helminthology | Cambridge Core (original) (raw)

Abstract

A study has been carried out to determine the morphological changes to the adult liver fluke, Fasciola hepatica after treatment in vivo with artemether. Rats were infected with the triclabendazole-resistant Sligo isolate of F. hepatica, dosed orally with artemether at a concentration of 200 mg/kg and flukes recovered at 24, 48 and 72 h post-treatment (p.t.). Surface changes were monitored by scanning electron microscopy and fine structural changes to the tegument and gut by transmission electron microscopy. Twenty-four hours p.t., the external surface showed minor disruption, in the form of mild swelling of the tegument. The tegumental syncytium and sub-tegumental tissues appeared relatively normal. Forty-eight and seventy-two hours p.t., disruption to the tegumental system increased, with isolated patches of surface blebbing and reduced production of secretory bodies by the tegumental cells being the main changes seen. The gastrodermal cells showed a relatively normal morphology 24 h p.t. By 48 h, large numbers of autophagic vacuoles and lipid droplets were present. Autophagy increased in magnitude by 72 h p.t. and substantial disruption to the granular endoplasmic reticulum was observed. Results from this study show that flukes treated in vivo with artemether display progressive and time-dependent alterations to the tegument and gut. Disruption to the gut was consistently and substantially more severe than that to the tegument, suggesting that an oral route of uptake for this compound predominates. This is the first study providing ultrastructural information on the effect of an artemisinin compound against liver fluke.

References

Álvarez-Sánchez, M.A., Mainar-Jaime, R.C., Pérez-García, J. & Rojo-Vázquez, F.A. (2006) Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain. Veterinary Record 159, 424–425.CrossRefGoogle ScholarPubMed

Bennett, C.E. (1975) Scanning electron microscopy of Fasciola hepatica during migration in the mouse. Journal of Parasitology 61, 892–898.CrossRefGoogle Scholar

Berman, P.A. & Adams, P.A. (1997) Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radical Biology and Medicine 22, 1283–1288.CrossRefGoogle ScholarPubMed

Boray, J.C. (1994) Disease of domestic animals caused by flukes. 49 pp. Rome, Food and Agricultural Organization of the United Nations.Google Scholar

Boray, J.C., Crowfoot, P.D., Strong, M.B., Allison, J.R., Schellenbaum, M., Von Orelli, M. & Sarasin, G. (1983) Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Veterinary Record 113, 315–317.CrossRefGoogle ScholarPubMed

Coles, G.C. & Stafford, K.A. (2001) Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica. Veterinary Record 148, 723–724.CrossRefGoogle ScholarPubMed

Coles, G.C., Rhodes, A.C. & Stafford, K.A. (2000) The activity of closantel against adult triclabendazole-resistant Fasciola hepatica. Veterinary Record 146, 504.CrossRefGoogle ScholarPubMed

Dubin, M. & Stoppani, A.O.M. (2000) Programmed cell death and apoptosis. The role of mitochondria. Medicina-Buenosa Aires 60, 375–386.Google ScholarPubMed

Eckstein-Ludwig, U., Webb, R., van Goethem, I., East, J., Lee, A., Kimura, M., O'Neill, P., Bray, P., Ward, S. & Krishna, S. (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957–961.CrossRefGoogle ScholarPubMed

Fairweather, I. (2005) Triclabendazole: new skills to unravel an old(ish) enigma. Journal of Helminthology 79, 227–234.CrossRefGoogle ScholarPubMed

Fairweather, I. (2009) Triclabendazole progress report, 2005–2009: an advancement of learning? Journal of Helminthology.CrossRefGoogle ScholarPubMed

Fairweather, I., Threadgold, L.T. & Hanna, R.E.B. (1999) . pp. 47–111_in_ Dalton, J.P. (Ed.) Fasciolosis. Wallingford, Oxon, CAB International.Google Scholar

Halferty, L., Brennan, G.P., Hanna, R.E.B., Edgar, H.W., Meaney, M., McConville, M., Trudgett, A., Hoey, L. & Fairweather, I. (2008) Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole. Veterinary Parasitology 155, 49–58.CrossRefGoogle ScholarPubMed

Hien, T.T., Truong, N.G., Minh, N.H., Dat, H.D., Dung, N.T., Hue, N.T., Dung, T.K., Tuan, P.Q., Campbell, J.I., Farrar, J.J. & Day, J.N. (2008) A randomised controlled pilot study of artesunate versus triclabendazole for human fascioliasis in Central Vietnam. American Journal of Tropical Medicine and Hygiene 78, 388–392.CrossRefGoogle ScholarPubMed

Jung, J., Kim, H., Nam, K.Y. & No, K.T. (2005) Three-dimensional structure of Plasmodium falciparum Ca-ATPase (PfATP6) and docking of artemisinin derivatives to PfATP6. Bioorganic and Medicinal Chemistry Letters 15, 2994–2997.CrossRefGoogle Scholar

Keiser, J. & Utzinger, J. (2007) Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Current Opinion in Infectious Diseases 20, 605–612.CrossRefGoogle ScholarPubMed

Keiser, J. & Morson, G. (2008a) Fasciola hepatica: tegumental alterations in adult flukes following in vitro and in vivo administration of artesunate and artemether. Experimental Parasitology 118, 228–237.CrossRefGoogle ScholarPubMed

Keiser, J. & Morson, G. (2008b) Fasciola hepatica: surface tegumental responses to in vitro and in vivo treatment with the experimental fasciolicide OZ78. Experimental Parasitology 119, 87–93.CrossRefGoogle ScholarPubMed

Keiser, J., Engels, D., Büscher, G. & Utzinger, J. (2005) Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opinion in Investigational Drugs 14, 1513–1526.CrossRefGoogle ScholarPubMed

Keiser, J., Xiao, S.H., Xue, J., Chang, Z.S., Odermatt, P., Tesana, S., Tanner, M. & Utzinger, J. (2006a) Effect of artesunate and artemether against Clonorchis sinensis and Opisthorchis viverrini in rodent models. International Journal of Antimicrobial Agents 28, 370–373.CrossRefGoogle ScholarPubMed

Keiser, J., Xiao, S.H., Tanner, M. & Utzinger, J. (2006b) Artesunate and artemether are effective fasciolicides in the rat model and in vitro. Journal of Antimicrobial Chemotherapy 57, 1139–1145.CrossRefGoogle ScholarPubMed

Keiser, J., Utzinger, J., Tanner, M., Dong, Y. & Vennerstrom, J.L. (2006c) The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. Journal of Antimicrobial Chemotherapy 58, 1193–1197.CrossRefGoogle ScholarPubMed

Keiser, J., Utzinger, J., Vennerstrom, J.L., Dong, Y., Brennan, G. & Fairweather, I. (2007a) Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Transactions of the Royal Society for Tropical Medicine and Hygiene 101, 1219–1222.CrossRefGoogle ScholarPubMed

Keiser, J., Xiao, S.H., Dong, Y., Utzinger, J. & Vennerstrom, J.L. (2007b) Clonorchicidal properties of the synthetic trioxolane OZ78. Journal of Parasitology 93, 1209–1214.CrossRefGoogle ScholarPubMed

Keiser, J., Rinaldi, L., Veneziano, V., Mezzino, L., Tanner, M., Utzinger, J. & Cringoli, G. (2008) Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep. Parasitology Research 103, 517–522.CrossRefGoogle ScholarPubMed

Lefèvre, G. & Thomsen, M.S. (1999) Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clinical Drug Investigation 18, 467–480.CrossRefGoogle Scholar

Li, Q.-G., Peggins, J.O., Fleckenstein, L.L., Masonic, K., Heiffer, M.H. & Brewer, T.G. (1998) The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. Journal of Pharmacy and Pharmacology 50, 173–182.CrossRefGoogle ScholarPubMed

Li, W., Mo, W., Shen, D., Sun, L., Wang, J., Lu, S., Gitschier, J.M. & Zhou, B. (2005) Yeast model uncovers dual roles of mitochondria in the action of artemisinin. PloS Genetics 1, 329–334.CrossRefGoogle ScholarPubMed

Mas-Coma, S., Bargues, M.D. & Valero, M.A. (2005) Fascioliasis and other plant-borne trematode zoonoses. International Journal for Parasitology 35, 1255–1278.CrossRefGoogle ScholarPubMed

Mason, R.P., Walter, M.F. & Mason, P.E. (1997) Effect of oxidative stress on membrane structure: small-angle X-ray diffraction analysis. Free Radical Biology and Medicine 23, 419–425.CrossRefGoogle ScholarPubMed

McConville, M., Brennan, G.P., Flanagan, A., Edgar, H.W.J., McCoy, M., Castillo, R., Hernández-Campos, A. & Fairweather, I. (2008) Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Veterinary Parasitology 153, 52–64.CrossRefGoogle ScholarPubMed

McConville, M., Brennan, G.P., Flanagan, A., Edgar, H.W.J., Hanna, R.E.B., McCoy, M., Gordon, A.W., Castillo, R.C., Hernández-Campos, A. & Fairweather, I. (2009a) An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica. Veterinary Parasitology .CrossRefGoogle ScholarPubMed

McConville, M., Brennan, G.P., Flanagan, A., Edgar, H.W.J., Castillo, R., Hernández-Campos, A. & Fairweather, I. (2009b) Ultrastructural changes to the tegumental system and the gastrodermal cells in mature flukes following in vivo treatment with the experimental fasciolicide, compound alpha. Parasitology .Google Scholar

McCoy, M.A., Fairweather, I., Brennan, G.P., Kenny, J.M. & Forbes, A.B. (2005) The efficacy of nitroxynil and triclabendazole administered synchronously against juvenile triclabendazole-resistant Fasciola hepatica in sheep. Research in Veterinary Sciences 78, 33.Google Scholar

McKinstry, B., Fairweather, I., Brennan, G.P. & Forbes, A.B. (2003) Fasciola hepatica: tegumental surface alterations following treatment in vivo and in vitro with nitroxynil (Trodax). Parasitology Research 91, 251–263.CrossRefGoogle ScholarPubMed

McKinstry, B., Brennan, G.P., Halferty, L., Forbes, A.B. & Fairweather, I. (2007) Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax). Parasitology Research 101, 929–941.CrossRefGoogle ScholarPubMed

McKinstry, B., Halferty, L., Brennan, G.P. & Fairweather, I. (2009) Morphological response of triclabendazole-susceptible and triclabendazole-resistant isolates of Fasciola hepatica to treatment in vitro with nitroxynil (Trodax). Parasitology Research 104, 645–655.CrossRefGoogle ScholarPubMed

Meaney, M., Fairweather, I., Brennan, G.P., McDowell, L.S.L. & Forbes, A.B. (2003) Fasciola hepatica: effects of the fasciolicide clorsulon in vitro and in vivo on the tegumental surface, and a comparison of the effects on young- and old-mature flukes. Parasitology Research 91, 238–250.CrossRefGoogle Scholar

Meaney, M., Haughey, S., Brennan, G.P. & Fairweather, I. (2005a) A scanning electron microscope study on the route of entry of clorsulon into the liver fluke, Fasciola hepatica. Parasitology Research 95, 117–128.CrossRefGoogle Scholar

Meaney, M., Haughey, S., Brennan, G.P. & Fairweather, I. (2005b) A scanning electron microscope study on the route of entry of clorsulon into the liver fluke, Fasciola hepatica. Parasitology Research 96, 189–198.CrossRefGoogle Scholar

Meaney, M., Haughey, S., Brennan, G.P. & Fairweather, I. (2005c) Ultrastructural observations on oral ingestion and trans-tegumental uptake of clorsulon by the liver fluke, Fasciola hepatica. Parasitology Research 95, 201–212.CrossRefGoogle ScholarPubMed

Meaney, M., Allister, J., McKinstry, B., McLaughlin, K., Brennan, G.P., Forbes, A.B. & Fairweather, I. (2006) Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitology Research 99, 609–621.CrossRefGoogle ScholarPubMed

Mitchell, G.B.B. (2002) Update on fasciolosis in cattle and sheep. In Practice 24, 378–385.CrossRefGoogle Scholar

Mottier, L., Alvarez, L., Fairweather, I. & Lanusse, C. (2006a) Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. Journal of Parasitology 92, 1355–1360.CrossRefGoogle ScholarPubMed

Mottier, L., Alvarez, L., Ceballos, L. & Lanusse, C. (2006b) Drug transport mechanisms in helminth parasites: passive diffusion of benzimidazole anthelmintics. Experimental Parasitology 113, 49–57.CrossRefGoogle ScholarPubMed

Navaratnam, V., Mansor, S.M., Sit, N.W., Grace, J., Li, Q. & Olliaro, P. (2000) Pharmacokinetics of artemisinin-type compounds. Clinical Pharmacokinetics 39, 255–266.CrossRefGoogle ScholarPubMed

Overend, D.J. & Bowen, F.L. (1995) Resistance of Fasciola hepatica to triclabendazole. Australian Veterinary Journal 72, 275–276.CrossRefGoogle ScholarPubMed

Robinson, G. & Threadgold, L.T. (1975) Electron microscope studies of Fasciola hepatica. XII. The fine structure of the gastrodermis. Experimental Parasitology 37, 20–36.CrossRefGoogle ScholarPubMed

Robinson, M.W., Trudgett, A., Hoey, E.M. & Fairweather, I. (2002) Triclabendazole-resistant Fasciola hepatica: β-tubulin and response to in vitro treatment with triclabendazole. Parasitology 124, 325–338.CrossRefGoogle ScholarPubMed

Rohn, T.R., Hinds, T.R. & Vincenzi, F.F. (1996) Inhibition of Ca2+-pump ATPase and the Na+/K+-pump ATPase by iron-generated free radicals. Protection by 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrol0[2,3-d]pyrimidine sulfate (U-89843D), a potent, novel, antioxidant/free radical scavenger. Biochemical Pharmacology 51, 471–476.CrossRefGoogle Scholar

Skuce, P.J. & Fairweather, I. (1990) The effect of the hydrogen ionophore closantel upon the pharmacology and ultrastructure of the adult liver fluke Fasciola hepatica. Parasitology Research 76, 241–250.CrossRefGoogle ScholarPubMed

Sumegi, B., Kovacs, K., Veres, B., Radnai, B., Varbiro, G., Bognar, Z., Toth, A. & Gallyas, F. (2005) . pp. 121–130_in_ Benedetti, A., Banhegyi, G. & Burchell, A. (Eds) Endoplasmic reticulum: a metabolic compartment . Amsterdam, IOS Press.Google Scholar

Threadgold, L.T. (1963) The tegument and associated structures of Fasciola hepatica. Quarterly Journal of the Microscopical Society 104, 505–512.Google Scholar

Threadgold, L.T. (1967) Electron-microscope studies of Fasciola hepatica. III. Further observations on the tegument and associated structures. Parasitology 57, 633–637.CrossRefGoogle Scholar

Toner, E., McConvery, F., Brennan, G.P., Meaney, M. & Fairweather, I. (2009) A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology .CrossRefGoogle Scholar

Uhlemann, A.-C., Wittlin, S., Matile, H., Bustamante, L.Y. & Krishna, S. (2007) Mechanism of antimalarial action of the synthetic trioxolane RBX1160 (OZ277). Antimicrobial Agents and Chemotherapy 51, 667–672.CrossRefGoogle ScholarPubMed

Utzinger, J., Xiao, S.-H., Tanner, M. & Keiser, J. (2007) Artemisinins for schistosomiasis and beyond. Current Opinion in Investigational Drugs 8, 105–116.Google ScholarPubMed

Wakabayashi, T. & Karbowski, M. (2001) Structural changes of mitochondria related to apoptosis. Biological Signals and Receptors 10, 26–56.CrossRefGoogle ScholarPubMed

Walker, S., McKinstry, B., Boray, J.C., Brennan, G.P., Trudgett, A., Hoey, E.M., Fletcher, H. & Fairweather, I. (2004) Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitology Research 94, 427–438.CrossRefGoogle ScholarPubMed

Wolstenholme, A., Fairweather, I., Prichard, R., Von Samson-Himmelstjerna, G. & Sangster, N. (2004) Drug resistance in veterinary helminths. Trends in Parasitology 20, 469–476.CrossRefGoogle ScholarPubMed

Xiao, S.-H., Wu, Y.-L., Tanner, M., Wu, W.-M., Utzinger, J., Mei, J.-Y., Scorneaux, B., Chollet, J. & Zhai, Z. (2003) Schistosoma japonicum: in vitro effects of artemether combined with haemin depend on cultivation media and appraisal of artemether products appearing in the media. Parasitology Research 89, 459–466.CrossRefGoogle ScholarPubMed